Determination of lansoprazole and its metabolites in plasma by high-performance liquid chromatography using a loop column.
A high-performance liquid chromatographic method for the simultaneous determination of lansoprazole, a new proton pump inhibitor, and its metabolites in human plasma is described. Lansoprazole, its metabolites and an internal standard were extracted with tert.-butyl methyl ether. Samples were injected using an automatic injector via a loop column, and separation was obtained using a reversed-phase column under isocratic conditions. The absorbance was monitored at 285 and 303 nm. The quantification limit was 2 ng/ml for lansoprazole and 3 or 5 ng/ml for the metabolites. No endogenous compounds were found to interfere. The mean overall recovery was between 75 and 95% for lansoprazole and its metabolites. This method is suitable for pharmacokinetic studies.
Landes
B D
BD
Laboratoire de Toxicologie et de Pharmacocinétique, Hôpital Ambroise Paré, Boulogne Billancourt, France.
Miscoria
G
G
Flouvat
B
B
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D000251:Adenosine Triphosphatases / Q000037:antagonists & inhibitors*; D000368:Aged; D002851:Chromatography, High Pressure Liquid / Q000379:methods*; D006801:Humans; D064747:Lansoprazole; D009853:Omeprazole / Q000031:analogs & derivatives* / Q000097:blood; D015203:Reproducibility of Results; D013056:Spectrophotometry, Ultraviolet
D053799:2-Pyridinylmethylsulfinylbenzimidazoles; D064747:Lansoprazole; D000251:Adenosine Triphosphatases; D009853:Omeprazole